Business Context and Reporting Period
This Form 8-K filing by IRADIMED CORP was submitted on September 13, 2018. The report addresses corporate governance changes approved by the Board of Directors on the same date. The company is incorporated in Delaware and identifies as an emerging growth company.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on amendments to the company's bylaws.
Material Changes
The Board of Directors approved amendments to the Company's Bylaws effective immediately. The primary change involves the removal of a fee-shifting provision. Previously, this provision required stockholders (or those acting on their behalf) who brought certain litigation against the Company or its directors, officers, employees, or affiliates to pay the Company's legal fees if they did not obtain a judgment on the merits that substantially achieved the full remedy sought.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific business risks. The removal of the fee-shifting provision is a governance adjustment intended to align with evolving legal standards regarding shareholder litigation rights, though the filing does not elaborate on specific risk implications beyond the text of the amendment.
Key Facts for Investor Verification
- The fee-shifting provision in the Bylaws has been removed effective September 13, 2018.
- The full text of the Amended Bylaws is available as Exhibit 3.2 to this filing.
- The company is classified as an emerging growth company and has elected not to use the extended transition period for new accounting standards.
- No financial performance data is included in this specific report.